Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Total Debt: 2013-2025

Historic Total Debt for Ironwood Pharmaceuticals (IRWD) over the last 10 years, with Sep 2025 value amounting to $584.5 million.

  • Ironwood Pharmaceuticals' Total Debt rose 46.13% to $584.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.9 billion, marking a year-over-year increase of 7.75%. This contributed to the annual value of $385.0 million for FY2024, which is 22.93% down from last year.
  • According to the latest figures from Q3 2025, Ironwood Pharmaceuticals' Total Debt is $584.5 million, which was up 0.03% from $584.3 million recorded in Q2 2025.
  • In the past 5 years, Ironwood Pharmaceuticals' Total Debt registered a high of $599.1 million during Q2 2023, and its lowest value of $112.9 million during Q2 2021.
  • In the last 3 years, Ironwood Pharmaceuticals' Total Debt had a median value of $487.2 million in 2023 and averaged $486.2 million.
  • Its Total Debt has fluctuated over the past 5 years, first fell by 29.06% in 2024, then skyrocketed by 46.13% in 2025.
  • Ironwood Pharmaceuticals' Total Debt (Quarterly) stood at $116.9 million in 2021, then reached $120.6 million in 2022, then reached $499.6 million in 2023, then dropped by 22.93% to $385.0 million in 2024, then skyrocketed by 46.13% to $584.5 million in 2025.
  • Its last three reported values are $584.5 million in Q3 2025, $584.3 million for Q2 2025, and $385.0 million during Q1 2025.